EE+ POEM Archive
Empiric treatment of onychomycosis with terbinafine is most cost-effective strategy
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Empiric Treatment of Onychomycosis With Terbinafine Is Most Cost-effective Strategy." EE+ POEM Archive, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314172/all/Empiric_treatment_of_onychomycosis_with_terbinafine_is_most_cost_effective_strategy.
Empiric treatment of onychomycosis with terbinafine is most cost-effective strategy. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314172/all/Empiric_treatment_of_onychomycosis_with_terbinafine_is_most_cost_effective_strategy. Accessed January 18, 2025.
Empiric treatment of onychomycosis with terbinafine is most cost-effective strategy. (2025). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314172/all/Empiric_treatment_of_onychomycosis_with_terbinafine_is_most_cost_effective_strategy
Empiric Treatment of Onychomycosis With Terbinafine Is Most Cost-effective Strategy [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2025. [cited 2025 January 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314172/all/Empiric_treatment_of_onychomycosis_with_terbinafine_is_most_cost_effective_strategy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Empiric treatment of onychomycosis with terbinafine is most cost-effective strategy
ID - 1314172
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314172/all/Empiric_treatment_of_onychomycosis_with_terbinafine_is_most_cost_effective_strategy
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
